Many supplements claim mood benefits. This guide ranks magnesium, ashwagandha, saffron, and others for anxiety and low mood by clinical evidence.
Supplements for Mood and Anxiety are among the most searched categories in the wellness space, yet the evidence behind them is wildly uneven. Some compounds have solid randomized controlled trial (RCT) data behind them; others ride on tradition, animal studies, and marketing. This article ranks the evidence for the most commonly discussed supplements, focusing on what human trials actually show—and where the data falls short.
What the Evidence Actually Shows
When evaluating supplements for mood and anxiety, the quality of evidence matters more than the number of anecdotes. The gold standard is the double-blind, placebo-controlled RCT in humans. Meta-analyses and systematic reviews sit at the top of the hierarchy. Animal studies, in vitro work, and mechanistic hypotheses are useful for generating hypotheses—but they do not prove efficacy in people.
Ashwagandha is the clearest example of a supplement with human RCT data directly addressing anxiety. Chandrasekhar et al. (2012) conducted a prospective, randomized, double-blind, placebo-controlled trial in adults with chronic stress. Participants receiving a high-concentration full-spectrum ashwagandha root extract showed significant reductions in stress-assessment scores and serum cortisol levels compared with placebo. The study was small—64 participants—but the design was rigorous. Pratte et al. (2014) later conducted a systematic review of human trial results for ashwagandha as an alternative treatment for anxiety, concluding that the available evidence suggests real anxiolytic potential, though larger and more diverse trials are needed.
Langade et al. (2019) extended this work to insomnia and anxiety, finding that ashwagandha root extract improved sleep quality and reduced anxiety scores in a randomized, double-blind, placebo-controlled study. These three human trials—Chandrasekhar (2012), Pratte (2014), and Langade (2019)—form the strongest evidence base for any single supplement in the mood and anxiety category.
Other supplements commonly discussed for mood—such as 5-HTP, St. John's wort, saffron, and various B-vitamin complexes—have mixed or preliminary human data. Some show promise in small trials; others have failed to replicate in larger studies. The honest assessment is that ashwagandha currently has the most coherent and replicated human evidence for anxiety reduction among over-the-counter supplements.
How Ashwagandha Works
Ashwagandha, Withania somnifera, is an adaptogen—a class of herbs thought to help the body adapt to stress. The active compounds, primarily withanolides, modulate the hypothalamic-pituitary-adrenal (HPA) axis, the body's central stress-response system.
Chandrasekhar et al. (2012) observed that ashwagandha supplementation reduced serum cortisol, the primary glucocorticoid released during stress. Lower cortisol is consistent with a dampened HPA-axis response. Whether this effect is direct—acting on the adrenal cortex or hypothalamus—or indirect via modulation of GABA receptors or inflammatory pathways is not fully resolved in humans. Animal and in vitro studies suggest withanolides may enhance GABAergic signaling and reduce pro-inflammatory cytokines, but human mechanistic data is limited.
What we know with reasonable confidence: ashwagandha appears to reduce perceived stress and cortisol in chronically stressed adults. The exact molecular pathway in humans remains under investigation. This is a common pattern in nutritional biochemistry—clinical efficacy sometimes precedes complete mechanistic understanding.
Evidence Comparison: What the Data Looks Like
The table below summarizes the key human trials on ashwagandha for stress, anxiety, and related outcomes. All studies used KSM-66 or similar full-spectrum root extracts.
| Study | Design | N | Dose | Duration | Primary Outcome | Evidence Quality |
|---|---|---|---|---|---|---|
| Chandrasekhar et al. (2012) | RCT, double-blind, placebo-controlled | 64 | 300 mg 2×/day | 60 days | Reduced stress scores and serum cortisol | Moderate |
| Langade et al. (2019) | RCT, double-blind, placebo-controlled | 60 | 300 mg 2×/day | 10 weeks | Improved sleep quality and reduced anxiety | Moderate |
| Pratte et al. (2014) | Systematic review of human trials | Varied | Varied | Varied | Consistent anxiolytic effects across trials | Moderate |
| Wankhede et al. (2015) | RCT, double-blind, placebo-controlled | 57 | 300 mg 2×/day | 8 weeks | Increased muscle strength and recovery; secondary stress markers | Moderate (primary outcome: strength) |
| Choudhary et al. (2017) | RCT, double-blind, placebo-controlled | 50 | 300 mg 2×/day | 8 weeks | Improved memory and cognitive function | Moderate (primary outcome: cognition) |
A few patterns emerge. First, the 300 mg twice-daily dosing (600 mg/day total) of a high-concentration extract appears consistently across trials. Second, effects are typically measured over 8–10 weeks, not days. Third, the sample sizes are modest—none exceed 64 participants. This limits how strongly we can generalize to broader populations.
Wankhede et al. (2015) and Choudhary et al. (2017) are worth noting even though their primary outcomes were muscle strength and cognitive function, respectively. Both reported secondary improvements in stress-related markers, suggesting the anxiolytic effects may be part of a broader adaptogenic profile. However, these were not powered or designed as anxiety trials, so the stress data should be treated as supportive, not definitive.
What the Evidence Does Not Show
It is equally important to be clear about what has not been demonstrated. No large-scale, multi-site RCT of ashwagandha for generalized anxiety disorder (GAD) or major depressive disorder (MDD) has been published. The existing trials focus on chronic stress and mild-to-moderate anxiety in otherwise healthy adults. We do not know if effects scale to clinical anxiety disorders, or if they persist beyond 10 weeks.
Head-to-head comparisons with pharmaceutical anxiolytics are absent. We cannot say whether ashwagandha is equivalent to, weaker than, or synergistic with SSRIs or benzodiazepines. Safety data in pregnancy, lactation, or pediatric populations is essentially nonexistent. And while the mechanism is partially understood, the human neuroimaging and receptor-binding studies that would clarify how withanolides act in the brain have not been done.
Finally, supplement quality varies enormously. The studies above used standardized, high-concentration extracts. A generic ashwagandha powder from an unverified source may contain different withanolide concentrations—or none at all. This is where reading labels matters. Our guide on How to Read Supplement Labels walks through what to look for in a standardized extract.
Who Benefits Most
The evidence is strongest for adults experiencing chronic stress or mild-to-moderate anxiety, particularly those with elevated cortisol levels. Chandrasekhar et al. (2012) specifically recruited adults with a history of chronic stress, and this is where the effect sizes were largest. If you are a high-functioning adult juggling work, sleep debt, and subclinical anxiety, the existing data is most relevant to you.
Athletes and physically active individuals may also see mood-related benefits, though the primary evidence here is secondary. Wankhede et al. (2015) showed improved recovery and strength in healthy men, with stress markers moving in a favorable direction. Whether this translates to reduced anxiety in non-athletic populations is plausible but unproven.
Individuals with diagnosed anxiety disorders, severe depression, or those taking prescription medications should not replace conventional treatment with ashwagandha without medical supervision. The existing trials do not establish efficacy in these populations, and herb-drug interactions—while not well-documented for ashwagandha—are always a consideration.
For those new to supplementation, starting with a single, well-evidenced compound is generally wiser than stacking multiple products. Our Supplement Beginner Guide covers how to introduce one supplement at a time and track your response.
Dosing, Form, and Timing
The human trials consistently used 600 mg/day of a high-concentration full-spectrum root extract, typically split into two 300 mg doses. This appears to be the evidence-based starting point. Lower doses may be marketed for general wellness, but they have not been tested in the RCTs cited here.
Form matters. KSM-66 is a branded full-spectrum extract with standardized withanolide content and the most trial data. Other extracts, such as Sensoril, use different ratios and may have different effects. If you are selecting a product, look for standardization: the label should specify withanolide percentage, typically 5% or higher in a quality extract.
Timing is less critical than consistency. Most trials administered doses with meals. Morning and evening splits are common. The key is daily use for at least 8 weeks before assessing efficacy. Adaptogens do not work acutely like benzodiazepines; their effects build over weeks of consistent use.
Bioavailability is another consideration. Withanolides are lipophilic compounds, and absorption may be enhanced by taking them with a fat-containing meal. For a deeper look at how formulation affects absorption, see our article on Bioavailability Explained.
Where does nicotinamide mononucleotide (NMN) fit in? NMN is a precursor to NAD+, a coenzyme involved in cellular energy metabolism and sirtuin activation. Some preclinical work suggests NAD+ pathways may influence stress resilience and neuronal health, but human trials specifically examining NMN for mood or anxiety are limited. If you are already taking a product like Bio:sudo NMN 1000mg for metabolic or longevity goals, there is no direct evidence it will address anxiety—but the mechanistic overlap with cellular stress pathways is an area of active research.
Practical Takeaways
- Ashwagandha has the strongest human evidence among over-the-counter supplements for reducing stress and mild anxiety, with multiple RCTs showing consistent effects on cortisol and perceived stress.
- Dose matters: 600 mg/day of a high-concentration full-spectrum extract (e.g., KSM-66) is the evidence-based dose used in trials. Lower doses are untested for anxiety.
- Give it time: Effects emerge over 8–10 weeks, not days. This is not an acute anxiolytic.
- Quality varies: Look for standardized withanolide content on the label. Unstandardized powders may not deliver the active compounds at effective concentrations.
- Do not replace clinical care: The evidence supports use in chronic stress and subclinical anxiety, not diagnosed GAD, MDD, or panic disorder. Consult a clinician if symptoms are severe or persistent.
- Start simple: Introduce one supplement at a time, track your response, and avoid stacking multiple unproven products.
Bottom Line
Supplements for Mood and Anxiety are not all created equal. Ashwagandha stands out for having multiple human RCTs with consistent results on stress and anxiety reduction, though the trials are small and the populations studied are limited. For other supplements in this category, the evidence is weaker, more preliminary, or based on non-human research. If you are considering a supplement for stress or anxiety, ashwagandha is the most evidence-backed place to start—at the right dose, for the right duration, and with realistic expectations about what the research does and does not show.
References
- Chandrasekhar K, et al. "A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults." Indian Journal of Psychological Medicine. 2012;34(3):255–262. [Source]
- Langade D, et al. "Efficacy and safety of ashwagandha (Withania somnifera) root extract in insomnia and anxiety." Medicine. 2019;98(37):e17186. [Source]
- Wankhede S, et al. "Examining the effect of Withania somnifera supplementation on muscle strength and recovery." Journal of the International Society of Sports Nutrition. 2015;12:43. [Source]
- Choudhary D, et al. "Efficacy and safety of ashwagandha (Withania somnifera) root extract in improving memory and cognitive functions." Journal of Dietary Supplements. 2017;14(6):599–612. [Source]
- Pratte MA, et al. "An alternative treatment for anxiety: a systematic review of human trial results reported for the Ayurvedic herb ashwagandha." Journal of Alternative and Complementary Medicine. 2014;20(12):901–908. [Source]